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ABSTRACT 
 
Objective: To determine the feasibility and optimal design of a randomised controlled 
trial (RCT) of Seizure First Aid Training For Epilepsy (SAFE).  
Design: Pilot RCT with embedded microcosting. 
Setting: Three English hospital emergency departments (EDs). 
Participants: Patients aged ≥16 with established epilepsy reporting ≥2 ED visits in 
the prior 12 months and their significant others (SO).  
Interventions: Patients (and their SO) were randomly allocated (1:1) to SAFE plus 
Treatment-As-Usual (TAU) or TAU alone. SAFE is a 4-hour group course.  
Main outcome measures: Two criteria evaluated a definitive RCT’s feasibility: i) 
≥20% of eligible patients needed to be consented into the pilot; ii) routine data on use 
of ED over the 12-months post-randomisation needed securing for ≥75%. Other 
measures included: eligibility; ease of obtaining routine data; availability of self-report 
ED data and comparability; SAFE’s effect; and intervention cost. 
Results: Of ED attendees with a suspected seizure, 424 (10.6%) were eligible; 53 
(12.5%) patients and 38 SOs consented. Fifty-one patients (and 37 SOs) were 
randomised. Routine data on ED use at 12-months was secured for 94.1%. Self-report 
ED data was available for 66.7%. Patients reported more visits compared to routine 
data. Most (76.9%) randomised to SAFE received it and no related serious adverse 
events occurred. ED use at 12 months was lower in the SAFE+TAU arm compared to 
TAU alone, but not significantly (Rate Ratio= 0.62, 95% confidence interval 0.33 to 
1.17). A definitive trial would need ~674 patient participants and ~39 recruitment sites. 
Obtaining routine data was challenging, taking ~8.5 months. 
Conclusions: In satisfying only one predetermined ‘stop/go’ criterion, a definitive RCT 
is not feasible. The low consent rate in the pilot raises concerns about a definitive 
trial’s findings external validity and means it would be expensive to conduct. Research 
is required into how to optimise recruitment from the target population. 
Trial registration number: ISRCTN13 871 327. 
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‘Strengths and limitations of this study’ (5 bullet points; one sentence each, relating 
to the methods) 
1. Randomisation was done remotely by computer and stratification factors and 
allocations concealed from those collecting baseline and follow-up data and 
analysing it.  
2. Participants were recruited from sites serving areas where social deprivation 
was high and epilepsy control poor and so similar to those where a definitive 
RCT would likely need to focus recruitment.  
3. We completed one of the few microcostings of a self-management intervention 
for epilepsy.  
4. Despite recruited patient participants stating sufficient ED use when screened, 
routine data subsequently suggested ~40% did not meet the inclusion criteria. 
5. We estimated the effect of SAFE only on the proposed primary outcome 
measure for a definitive RCT. 
 
KEY WORDS: Epilepsy; Accident & Emergency Medicine; Organisation of health 
services; Health economics; Clinical Trials. 
 
Words: 3,955 
.
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1. BACKGROUND 1 
International evidence shows a significant minority of people with epilepsy (PWE) 2 
frequently use hospital emergency departments (EDs).1-4 In the United Kingdom (UK), 3 
around 20% of PWE visit each year, half are admitted 5-7. Whilst the exact distribution 4 
of use amongst attendees is unclear,8-10 ~60% may make several visits each year.11 5 
 6 
Emergency hospital use by PWE has been identified as an area for potential cost 7 
savings 12 as whilst expensive – ~£70-90M in England each year 8 13 14 – it is often of 8 
little clinical benefit since most attendees have known, rather than new epilepsy and 9 
experienced uncomplicated seizures.9 15-17 Guidance states such seizures could be 10 
managed by PWE and their significant others (SOs).18 19 Indeed, iatrogenic harms may 11 
arise in seeking emergency care for them.  12 
 13 
PWE visiting EDs have a characteristic profile. They report more seizures, anxiety, 14 
poorer quality of life and are more likely to live in socially deprived areas compared to 15 
the wider epilepsy population.11 20-23 They therefore share some of the characteristics 16 
of those at increased risk of epilepsy associated death.24 25 In the UK, PWE visiting 17 
EDs can also be challenging to identify for research since most (~62%) are not being 18 
followed-up by an epilepsy specialist,1 primary care providers are also not always 19 
notified of ED visits by their patients 9 and because EDs do not always code the reason 20 
for an attendance.26  21 
 22 
Whilst the focus on PWE attending EDs is welcomed, it needs to be translated into 23 
care improvements. Although a range of promising interventions have been 24 
suggested,27 assessment of their utility is lacking.28 25 
 26 
One intervention proposed is seizure first aid training. It has potential as PWE 27 
frequently visiting EDs and their SOs (to whom care decisions can be delegated 29 30) 28 
express particularly low knowledge and confidence in this domain, are fearful of 29 
seizures, and there are indications this leads them to seek emergency medical 30 
attention for seizures, rather than self-managing them.31  31 
 32 
As no such intervention existed, we developed one – called Seizure First Aid Training 33 
For Epilepsy (SAFE). SAFE is a manualised group-based self-management course 34 
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(Table 1). It’s rationale and development has been reported.32 In brief, it was co-1 
designed with health professionals, patients and carers. It was developed for delivery 2 
to groups of up to 10 patient-carer dyads by a single facilitator with knowledge of 3 
epilepsy and lasts for ~4 hours. It contains 6 modules centred around basic epilepsy 4 
and first aid knowledge, the recovery position, informing others about epilepsy and 5 
how to help if seizures occur, medical identification, seizure triggers and home safety. 6 
Materials include presentation slides and professionally produced videos. Its 7 
behaviour change potential has been optimised by course recipients completing a 8 
Self-Affirmation exercise at the start. 9 
 10 
SAFE’s efficacy now needs testing. A randomized controlled trial (RCT) would be an 11 
appropriate methodology for this. ED use over the 12 months following randomisation 12 
could be the primary outcome. It is unknown though whether such a trial is feasible 13 
and what its optimal design should be. 14 
 15 
Specifically, will patients and their SOs take part, attend SAFE, and be willing and able 16 
to be followed-up? It is also not possible to calculate the required sample size because 17 
the distribution of ED use is unclear. These uncertainties exist because SAFE is newly 18 
developed and no RCT has attempted to recruit the target population.  19 
 20 
It is also unclear how to measure ED visits. Funders are encouraging trialists to use 21 
routinely recorded data to assess outcomes. In England, routine data on a person’s 22 
ED use is recorded within the Hospital Episode Statistics system. This data’s cost, 23 
how long it takes to obtain and its comparability to self-report is though unknown.   24 
 25 
In such circumstances, guidelines highlight the importance of pilots.33 Their primary 26 
focus is not effect, but judging feasibility and providing information to optimise a 27 
definitive RCT’s design.34 We thus completed a pilot RCT comparing SAFE, plus 28 
treatment-As-Usual (TAU) to TAU alone. It had the following objectives, which will be 29 
relevant to those interested in SAFE and those researching this population: 30 
 31 
i) Estimate likely eligibility, consent, and retention rates in a definitive RCT; 32 
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ii) Estimate annual rate of ED visits in TAU group and the likely dispersion 1 
parameter;  2 
iii) Determine feasibility of measuring ED use by routine data; 3 
iv) Estimate completion rates of study assessment tools;  4 
v) Estimate rates of researcher unblinding;  5 
vi) Provide summary statistics to estimate effect of SAFE on ED use and its 6 
precision;  7 
vii) Capture patient and SOs views on trial participation; 8 
viii) Estimate the intervention’s cost. 9 
 10 
2. METHODS 11 
The trial’s protocol has been published.31 Here we provide a brief overview. 12 
 13 
2.1 Design 14 
Parallel arm, multicentre, external pilot RCT. Assessments with participants on the 15 
definitive trial’s proposed primary and secondary outcome measures were performed 16 
at baseline prior to randomization (T0) and 12-months later (T3) (Table 2). Interim 17 
assessments occurred at 3 (T1) and 6-months (T2).  18 
 19 
SAFE was offered to the TAU alone group after T3 assessments were completed. 20 
 21 
2.2 Trial setting 22 
Three hospitals in North-West England – which serve populations featuring high social 23 
deprivation 35 36 and emergency admissions for epilepsy 22 – were recruitment sites 24 
(Acknowledgements). From May to December 2016 patients were invited who had 25 
attended any of these hospital’s ED over the prior 12 (and with governance approval, 26 
later extended to 18) months for epilepsy (see 2.4).   27 
 28 
2.3 Ethical considerations and approvals  29 
The National Research Ethics Service Committee (15/NW/0225) and Health Research 30 
Authority (166241) approved the study. An independent Trial Steering Committee 31 
monitored it.  32 
 33 
2.4 Patient recruitment 34 
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ED clinicians searched their hospitals’ attendance record systems for potential 1 
participants (Supplementary File 1), screened their triage cards and posted invitations 2 
to eligible patients. Recipients had 3 weeks to return an opt-out response if not 3 
interested in participating. Those not opting-out were telephoned by a researcher to 4 
verify eligibility and willingness to participate. Patients taking part (and their SO if they 5 
chose to take part with one) provided informed consent at an enrolment appointment 6 
with a researcher (DS). For patients, this included consent to access their routine data.  7 
 8 
2.5 Eligibility criteria 9 
Table 3 details the criteria. In brief, patients were eligible if they were aged ≥16, 10 
diagnosed with epilepsy, prescribed antiepileptic drugs, could give informed consent 11 
and, when telephoned, self-reported ≥2 ED visits for epilepsy in the prior 12 months.  12 
 13 
2.6 Randomization and blinding 14 
Patients (and their SOs) were randomised (1:1) by an online system managed by the 15 
Liverpool Clinical Trials Centre. It used a minimisation program with a built-in random 16 
element and two stratification factors (recruitment site and whether the patient 17 
reported epilepsy stigma at baseline).  18 
 19 
Usual care provider(s) and DS, who was responsible for recruitment and follow-up, 20 
were blinded to allocations and stratification factors. Participants could not be blinded 21 
and so were asked not to reveal their allocation to DS.  22 
 23 
Staff (GM) organizing attendance at SAFE were not involved in data collection and not 24 
blinded. The trial (SN) statistician and senior statistician (CTS) were blinded until the 25 
database was ‘locked’. 26 
 27 
2.7 Measures to assess patient and SOs participants’ outcomes 28 
Table 2 details these measures.  29 
 30 
2.8 Intervention 31 
An epilepsy nurse specialist (JB) delivered SAFE within a local hospital’s educational 32 
centre. A fidelity assessment found they delivered SAFE with excellent protocol 33 
adherence and competence.37 34 
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 1 
2.9 Outcomes 2 
To achieve the study objectives, rates of eligibility, consent and retention were 3 
calculated. Retention being the percentage of patients for which 12-month primary 4 
outcome data was secured. Two a priori progression criteria helped judge feasibility: 5 
i) ≥20% of eligible patients were recruited; ii) 12-month primary outcome data secured 6 
for ≥75% of patients. 7 
 8 
By assessing participants on the proposed outcome measures, we obtained estimates 9 
of the distribution of ED use, measure completeness and SAFE’s effect. To evaluate 10 
blinding, DS completed a ‘Treatment Guess’ form after each participant’s T3 11 
assessment or withdrawal. It required her to state which treatment arm she believed 12 
the participant had been randomised to. The proportion of participants willing to 13 
participate in such a trial again was ascertained and experience of adverse events 14 
calculated. Time taken to obtain routine data and the fee payable was recorded. To 15 
see if self-reported ED visits provided a reliable estimate compared to routine data the 16 
agreement between the two data sources on how many ED visits a patient had made 17 
was explored.  18 
 19 
2.10 Statistical analyses 20 
As this was a pilot RCT, a power calculation was inappropriate. Instead, the sample 21 
size was chosen to provide adequate precision to estimate the parameters required.38  22 
Based on existing data,1 14 17 39 40 it was anticipated 12 months of attendances from 23 
each ED would allow identification of ~400 eligible patients. With a 20% consent rate, 24 
80 patient participant accruals could be expected. With 80 patient participants we 25 
could estimate a potential drop-out rate of 25% to within a 95% confidence interval of 26 
+/-10% and a consent rate of 20% to within a 95% confidence interval of +/-4%. 27 
Assuming ED data at T3 was not available for 25% of patients, data from 60 patients 28 
would still allow robust estimation of the ED rate and dispersion parameter. Sample 29 
sizes of 24 to 50 have been recommended as ‘adequate’ for pilot studies.38 41  30 
Analyses were documented a priori in an analysis plan and performed using SAS (9.4). 31 
Baseline characteristics for patient and SO participants are described using 32 
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descriptive statistics and patient participants compared, on a subset, to eligible 1 
patients declining participation. Parameters are reported with 95% confidence 2 
intervals (CIs).  3 
 4 
SAFE’s effect on ED use, with and without adjustment for number of ED visits prior to 5 
randomisation, was estimated using negative binomial regression (NBR) on a modified 6 
intention-to-treat basis (as defined by Del Re et al.42). Participants were included with 7 
their number of ED visits recorded with no data imputation. NBR was the pre-specified 8 
statistical approach as over-dispersion (i.e. large variance) was anticipated in the 9 
number of ED visits reported. Between-group differences are presented as Rate 10 
Ratios and, as per recommendations for hypothesis testing within pilot trials,43 tested 11 
according to 5, 10 and 20% levels of significance.  12 
 13 
The proportion of correct treatment guesses was determined and Cohen’s Kappa 14 
computed. Bland-Altman plots compared ED visits as measured by routine data and 15 
self-report.44 16 
 17 
As no consensus exists about what constitutes a clinically important reduction in ED 18 
visits,45 average annual rate of ED visits in the SAFE+TAU and TAU alone groups post 19 
randomisation (measured according to routine data) and the likely dispersion 20 
parameter from the adjusted NBR model were used to estimate the sample size of a 21 
definitive trial using Keene et al.’s 46 formula. According to the formula, the number of 22 
patient participants required per group in a definitive trial to detect the size of the effect 23 
shown in the pilot study is:  24 
 25 
Where Z1-α/2 and Z1-β are critical values of the Normal distribution for specific values of 26 
alpha (α) and power (β). µ1 and µ2 are the estimated ED rates from the two treatment 27 
groups and k the negative binomial shape parameter from the associated gamma 28 
distribution which explicitly represents variability between subjects. For the 29 
calculations, alpha was set at 5%, but the dispersion parameter and power required 30 
was varied to explore differences in sample size required.  31 
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 1 
2.11 Microcosting 2 
Microcosting adopted the perspective of an academic non-profit making institution and 3 
conducted in three steps:47 (1) resource identification; (2) resource use measurement, 4 
applying the time and motion method;48 and (3) valuation using price year 2017/18 for 5 
local and national data. Data were analysed using Microsoft Excel to calculate the 6 
fixed and variable costs of delivering SAFE.  Fixed costs included, equipment, website, 7 
freepost licence, venue hire, facilitator staff cost, and facilitation resources; and 8 
assumed 11 groups/year and equipment life of 1-year.  Variable costs were support 9 
staff and office costs, staff and participant travel expenses, and consumables.  Total 10 
cost per group was calculated as fixed costs plus variable costs, for each group and 11 
each arm (SAFE+TAU; TAU).  Mean cost per group was calculated as the sum of total 12 
costs / number of groups.  Mean cost per delegate (or patient only) were calculated 13 
as sum of total cost per group in each arm / sum of delegates (or patients only) in each 14 
arm.  Results are presented as: cost per training session, mean cost per delegate, 15 
mean cost per patient.  The 95% central range (CR) for costs and differences were 16 
generated using  Monte Carlo Simulation of 10,000 replications.   17 
 18 
2.12 Patient and Public Involvement statement  19 
This research came about as improving education for patients and families on epilepsy 20 
is a top research priority.49 To ensure SAFE was developed and tested in a way that 21 
met service users' needs: the ‘Epilepsy Society’ and patient and SO representatives 22 
from the ‘Brain and Spine Foundation’ helped develop recruitment materials; the pilot 23 
was overseen by a Trial Steering Committee including 2 service user representatives; 24 
SAFE’s was designed by an Intervention Panel including 2 service user 25 
representatives and its content informed by feedback from 23 service users;32 finally, 26 
pilot trial participants reported on the burden of participation with a view to optimising 27 
the design of a potential definitive RCT. 28 
 29 
3. RESULTS 30 
3.1 Participant recruitment, allocation and treatment 31 
Of the 4016 individuals identified, 1220 (30.4%, CI 29.0% to 31.8%) had visited for 32 
established epilepsy. Of these, 424 (34.8%, CI 32.1% to 37.4%) were eligible; eligibility 33 
rate 10.6% (CI 9.6% to 11.5%) (Figure 1 and Supplementary File 2).  34 
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 1 
Of the 424 patients invited, 53 consented; consent rate 12.5% (CI 9.3% to 15.6%). 2 
Telephone contact could though only be made with 203 (47.8%, CI 43.1% to 52.6%) 3 
patients. The consent rate amongst those who could be contacted was 26.1% (CI 4 
20.0% to 32.2%). The main reasons for 150 patients declining participation were “lack 5 
of interest” (42.7%, CI 34.8% to 50.6%) and being “too busy” (22.6%; CI 16.0% to 6 
29.4%).  7 
 8 
Of the 53 consenting patients, 51 were randomised (with 37 SOs) (Figure 1 gives 9 
reasons for non-randomisation). Of the 51, 26 (and 18 SOs) were allocated to 10 
SAFE+TAU and 25 (and 19 SOs) to TAU alone. Most (20, 76.9%) patients and SOs 11 
(13, 72.2%) randomized to SAFE+TAU attended a course.  12 
 13 
3.2 Participant demographics and epilepsy characteristics  14 
The patient participants mean age was 39.9 years (SD 15.7, range 16-71); 29 (56.9%) 15 
were female and most (74.4%) lived in areas high in deprivation (49% in the 10 percent 16 
most socially deprived areas in England) (Table 4).  17 
 18 
Recruited patients were comparable in age and deprivation to those declining 19 
participation. Females were though over-represented (Table 4). 20 
 21 
Recruited patients had an epilepsy diagnosis for a median of 17.3 years. Most (62.8%) 22 
reported ≥10 seizures in the previous year and having seen a neurologist (74.5%) 23 
(Table 4). Participants’ mean Quality of Life 31-P score was low at 48.3 (SD 17.3; 24 
range 17.1 to 79.5). Twenty-six (50.9%) had ‘probable’ clinical anxiety. Most (n=42, 25 
82.3%) reported feeling stigmatised by epilepsy; 15 (29.4%) highly. The treatment 26 
groups were broadly similar in demographics and epilepsy characteristics.  27 
 28 
SO participants were typically a partner/spouse (43.2%) and most (89.2%) had daily 29 
patient contact (Supplementary File 3). With a mean Zarit Caregiver burden score of 30 
18.9 (SD=12.51), SOs typically reported ‘little or no burden’ 50 but anxiety was high 51; 31 
15 (40.5%) SOs had ‘probable’ clinical anxiety.  32 
3.3 Participant retention  33 
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3.3.1 Proposed primary outcome measure:  1 
Of the randomised patients, 3 (5.8%) formally withdrew over follow-up, removing 2 
access to their routine data. Primary outcome data on ED use at 12 months (and for 3 
the 12 months prior to randomisation) was available for the remaining 48 patients, 4 
giving a retention rate of 94.1%.  5 
 6 
3.3.2 Proposed secondary outcome measures:  7 
Thirty-seven (72.5%) randomised patients and 21 (56.8%) SOs attended their 12-8 
months questionnaire appointment (T3). The extent to which measures were 9 
completed at these and the interim appointments varied (Supplementary File 4). Self-10 
report data on ED use at T3 was obtained from only 34 patients, giving a retention rate 11 
on this measure of 66.7% patients. 12 
3.4 ED use  13 
3.4.1 Baseline, prior to randomisation: 14 
Routine data for the 48 patients for whom consent was maintained showed they made 15 
122 ED visits in the 12 months before randomisation (Supplementary File 5). The 16 
mean was 2.5 and median 2 (range 0 to 12). ED use was slightly higher for TAU 17 
participants (Table 5). 18 
 19 
Despite only consenting patients who when telephoned reported ≥2 ED visits in the 20 
prior 12 months, routine data indicated 4 (8.3%) had not made any visits during the 21 
prior 12 months. A further 19 (39.6%) made only one.  22 
 23 
3.4.2 At 12 months, effect of SAFE: 24 
Compared to the 12-months prior to randomisation, mean ED use over follow-up 25 
reduced for the SAFE+TAU group from 2.1 visits to 1.8 (difference -0.3). For the TAU 26 
group, it increased from 3 visits to 3.4 (difference 0.4) (Table 5). Unadjusted NBR 27 
estimated the visit rate was 46% lower in the SAFE+TAU group compared to the TAU 28 
group (Rate Ratio= 0.54; Vuong’s test z=-0.17, P=0.87). In the adjusted model, 29 
SAFE’s effect reduced (Rate Ratio= 0.62). Between group differences were not 30 
significant at the 5% or 10% alpha level in either the unadjusted or adjusted model. 31 
The effect was significant in both at the 20% level (Table 6). The dispersion parameter 32 
under the adjusted NBR model was k=0.69 (CI 0.17 to 1.21).  33 
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 1 
3.5 Obtaining routine data and its correspondence with self-report  2 
Routine data took 8.5 months to secure, arriving ~9 months after T3 assessments 3 
finished. The direct cost was £6960. Supplementary File 6 shows substantial work on 4 
behalf of the research team to obtain the data was required. In one instance, an appeal 5 
against a decision to reject the application – 5 months in – was necessary. 6 
 7 
Routine data did not match patient self-report in most cases. Forty-two patients had 8 
self-report and routine data on ED use at baseline. Only 3 (7.1%) reported the same 9 
number of visits as their routine data indicated. Most (76.2%) reported more (by 3.8 10 
visits on average) (Figure 2a). There was greater agreement between routine and self-11 
report data at T3; 11 (32.4%) patients reported the same number of visits as their 12 
routine data (Figure 2b).  13 
 14 
3.6 Blinding 15 
The researcher correctly guessed which of the two treatment arms35 patient 16 
participants had been allocated to by the randomisation process; unblinding rate 17 
68.6% (CI 54.1% to 80.9%). The chance-corrected kappa statistic of 0.37 (CI 0.12 to 18 
0.63) equated to “fair” agreement.  19 
 20 
3.7 Safety  21 
No serious adverse events related to participation occurred (Supplementary File 7).  22 
 23 
3.8 Participant feedback 24 
Thirty-two (68.1%) patients and 20 (62.5%) SOs completed the T3 feedback 25 
questionnaire. All but one said they would participate in such a trial again; participants 26 
indicated they perceived benefits from SAFE. 27 
 28 
3.9 Sample size calculation 29 
Based on the estimated effect of SAFE (see 3.4.2), Table 7 shows the number of 30 
patient participants required per group for a definitive trial. If the central value in the 31 
estimate range for the dispersion parameter k of 0.69 is used and 90% power 32 
stipulated, then a total starting sample of 674 patient participants (i.e., [308*2]+58) 33 
would need to be recruited. This accounts for the 9.4% of recruited patients who (on 34 
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the basis of the pilot trial) would be anticipated to withdraw consent to access their 1 
routine ED data. In the pilot, 5 of the 53 patients recruited withdraw consent. 2 
 3 
3.10 Microcosting 4 
Delivering SAFE was estimated to cost £333 (CR £288 to £380) per patient (with or 5 
without a SO). When including the cost SAFE’s development (£181 per person), the 6 
mean cost per attendee, based on all 55 participants in SAFE+TAU or TAU groups 7 
who ultimately attended a SAFE session, was £375 (CR £348 to £402) 8 
(Supplementary File 8). This reduced to  £194 (CR £167 to £221) when excluding sunk 9 
costs. Staff time accounted for 50.01% of the cost of SAFE’s delivery. SAFE’s 10 
facilitator was not local to the trial area. Thus, an analysis of facilitator costs without 11 
travel expenses (time and cost), reduced the mean cost by 21.08% from £194 (CR 12 
£167 to £221) to £152 (CR £124 to £179) per delegate (£261 per patient with or without 13 
SO). The annual fixed cost of setting-up and running SAFE was £1122 (+£35.07 per 14 
patient, based on 32 patients/year attending with or without SO). 15 
 16 
4. DISCUSSION 17 
The pilot was successful, providing estimates of key parameters, including recruitment 18 
and retention. An informed decision regarding feasibility and optimal design of a 19 
definitive trial of SAFE can now be made.  20 
4.1 Positives from pilot for feasibility and design of definitive trial 21 
4.1.1 Identification, treatment and safety:  22 
The pilot indicates it is possible to identify, consent, randomise and safely treat 23 
persons from the target population within a definitive trial. This was not a given since 24 
no RCT had focused recruitment on them.  25 
 26 
4.1.2 Retention and measuring ED use: 27 
By using routine data as the basis of the primary outcome measure, a definitive trial 28 
should not be affected by attrition. It permitted 12-month data to be secured for 94% 29 
of pilot participants. Despite having shorter-follow-ups (6 months), 151 definitive RCTs 30 
funded by the NIHR secured outcome data for 89% of patients.52 The use of routine 31 
data in our pilot meant it satisfied the retention progression criterion. It would not have 32 
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been met if self-report data were relied on (only 67% of patients provided it). This leads 1 
us to recommend ED use be measured using routine data.  2 
 3 
Another reason for the recommendation is its cost would be low compared to 4 
employing staff to obtain self-report data. Routine data would also prevent a definitive 5 
trial from exposure to apparent recall bias, with patients seemingly over reporting ED 6 
use (it has been asserted bias is not an issue for ‘‘big ticket’’ service items).53 54  7 
 8 
Our pilot does though caution that provision of routine data is slow and not 9 
straightforward. It took 8.5 months to obtain. In principle, such applications should be 10 
processed within 2 months.55 Data providers should attend to such issues as those 11 
funding and designing trials need confidence data can be secured and realistic 12 
estimates for when.  It is also worth noting that some of the ED visits attributed to our 13 
participants may not have been epilepsy related. Since a diagnostic code is not 14 
recorded for ~35% of ED visits, we asked NHS Digital to inform us of any ED visits 15 
recorded for our participants.26 16 
 17 
4.2 Negatives from pilot for feasibility and design of definitive trial 18 
4.2.1 Consent: 19 
Only a small proportion of identified patients were eligible (10.6%) and willing (12.5%) 20 
to take part, meaning the progression criterion that ≥20% of eligible patients agree to 21 
participate was not met.  22 
 23 
The progression criterion was stated a priori because when uptake is so low there is 24 
the real possibility that those who are and are not taking part differ. We compared the 25 
age and deprivation of patients who did and did not take part and found no obvious 26 
differences. We do not know though whether they differed on other indices since 27 
access to non-participants’ medical records was not ethically permissible. One 28 
indication the pilot might not have recruited a representative sample was the high 29 
proportion of patients seeing a neurologist in the prior 12 months (~75%). Evidence 30 
suggests this should be closer to 38%.1 31 
The consent rate also raises questions over the likelihood of a definitive trial being 32 
funded since it would make it expensive. On average, each pilot site generated 17.6 33 
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patient accruals from 18 months of attendances. To achieve a sample size of ~674 1 
PWE, a definitive trial could thus require ~39 sites (half of England’s EDs). This is 2.5 2 
times more sites than in recent NIHR HTA funded RCTs 52 which already had a mean 3 
cost of ~£1.3M.56 A definitive RCT of SAFE might thus not represent acceptable value 4 
for money to funders.57  5 
Epilepsy and its consequences (e.g., seizures, memory difficulties, no driving license) 6 
makes recruiting PWE challenging. The consent rate in the pilot is nevertheless low. 7 
In the largest RCT of self-management (SMILE trial), 37% of the people with 8 
uncontrolled epilepsy invited took part.58 The characteristics of the patients from ED 9 
agreeing to participate in our pilot suggests one reason for the low uptake might be 10 
stigma; 82% felt some (21.6% felt highly stigmatised). This is higher than in the wider 11 
epilepsy population; 63% of SMILE’s sample felt stigmatised (12.5% highly).59 Stigma 12 
can make PWE feel ashamed and reluctant to talk about epilepsy. This could explain 13 
why the target population is so challenging to recruit. Unfortunately, it is unclear how 14 
to revise recruitment to mitigate against this.  15 
 16 
Evidence-based strategies were employed in the pilot to maximise recruitment,31 and 17 
invitation materials co-produced with patients. It is generally considered preferable 18 
though for a usual care provider, with whom a patient has an established relationship, 19 
to invite a person into research. Difficulties identifying the target population (see 1.0) 20 
meant we had local ED clinicians do the inviting. A future trial might consider asking 21 
EDs to identify ostensibly eligible patients, but for the GPs of the identified patients to 22 
do the inviting. This may boost recruitment.60 23 
 24 
 25 
4.2.2 Effect of intervention:  26 
Our pilot estimated SAFE’s effect to be modest (reducing ED visits from 2.1 over 12-27 
months to 1.8). This has negative consequences for a definitive trial, not least because 28 
it requires it to have a large sample to detect the effect. Efficacy was not though our 29 
pilot’s primary focus and the estimate may be imprecise. Indeed, it might be that those 30 
who declined to participate in the trial and who appeared to differ in some important 31 
ways, might have benefited more. Previous evidence does though suggest it is in the 32 
region expected.  33 
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 1 
Specifically, only one RCT – by Sajatovic et al.61  – has considered change in ED use 2 
following epilepsy self-management.62 Conducted in the U.S. it compared SMART – 3 
an 8-session group intervention – to wait-list control. No significant change between 4 
groups was found in subsequent ED/ hospitalization use. For SMART, it reduced from 5 
a mean of 1.22 by .44 over the 6 months following randomisation. For the controls it 6 
reduced from 2.4 by -1.26 visits.  7 
 8 
4.3 Judgement regarding progression to definitive trial 9 
Thabane et al.63 provide a framework for judging whether to progress to a definitive 10 
trial. In satisfying only one progression criteria, a definitive trial based on the pilot’s 11 
design is not feasible. We have also not identified any modifications that will make it 12 
feasible. We therefore recommend not proceeding.  13 
 14 
4.4 Strengths and limitations 15 
Strengths include the pilot being reported according to guidelines,64 allocations being 16 
concealed, that patients were recruited from sites similar to those likely for a definitive 17 
trial and we included a microcosting of SAFE’s delivery.   18 
 19 
The pilot is not without potential weaknesses. Most importantly, despite recruited 20 
patient participants stating sufficient ED use when screened, routine data 21 
subsequently suggested ~40% did not meet the inclusion criteria. This could limit our 22 
findings external validity and attenuate SAFE’s effect. Another potential limitation is 23 
we estimated the effect of SAFE only on the proposed primary measure. We did not 24 
estimate its wider effects, including on duration of ED visits and admissions.  25 
 26 
5. CONCLUSION 27 
A definitive trial of SAFE is not currently feasible. Research is required to determine 28 
how people from the target population can be better recruited. 29 
 30 
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Table 1 SAFE course and its content  
Overview 
SAFE was developed to be delivered to groups of ~10 patient-SO dyads by a single facilitator with epilepsy knowledge who follows a 
treatment manual. Materials include standardised presentation slides, videos and interactive tasks. Patients are given information 
packs that include copies of the slides, wallet sized first aid instructions cards, paper epilepsy ID Cards and instructions for setting up 
IDs on smart-phone, and access to a website with the intervention’s content on.  
 
SAFE’s behaviour change potential is supported by reference to Self-Affirmation Theory.  
 
SAFE’s order of presentation and content is as follows: 
 
Order Topics Learning 
activity 
Minutes 
allotted 
1 Welcome Slide 5 
2 Goals of this course Slide 2 
3 What would you like from today? Interactive 20 
4 True or false? Interactive 12 
5 Taking on information (Kindness Questionnaire) Interactive 10 
6 Epilepsy, seizures & how the brain works Video 10 
7 First aid for convulsive seizures Interactive 10 
8 What can you do to help someone during a seizure? Slide 5 
9 What not to do during a seizure Slide 5 
10 What to do after the seizure has stopped Slide 5 
11 Questions or comments? Interactive 10 
12 Post-seizure states Slide 15 
13 Injuries Slide 2 
14 When to call an ambulance? Slide 10 
15 Questions or comments? Slide 10 
16 Refreshment break Networking 10 
17 Recovery position Slide 2 
18 Recovery position Video 2 
19 Let’s practice the recovery position Interactive 15 
20 Questions or comments? Interactive 5 
21 Who needs to know how to help? Interactive 5 
22 What they need to know & why Slide 5 
20 
 
23 How to get this information to them. Family, friends & work colleagues: Slide 5 
24 How to get this information to them. Members of the public and health workers: Slide 5 
25 Questions or comments? Interactive 5 
26 Refreshment break Networking 5 
27 Personal stories - introduction Slide 2 
28 Ben’s story (case vignette) Slide 6 
29 How to change what happened to Ben? (Carrying medical ID; triggers) Interactive 5 
30 Triggers Slide 5 
31 Knowing your triggers Slide 4 
32 Some ways of dealing with triggers Slide 4 
33 Sandra’s story (case vignette) Slide 6 
34 How to change what happened to Sandra (Warning signs; home safety) Interactive 2 
35 Main points to remember, If you have epilepsy: Slide 3 
36 Main points to remember; If you know someone with epilepsy: Slide 2 
37 Sources of further information Slide 2 
38 What’s on the back table and accessing the study website* Slide 2 
39 Questions or comments? Slide 2 
40 Evaluation  - 
41 Certificates of attendance  - 
Time in minutes: 240 
Notes: 
* http://www.seizurefirstaid.org.uk/Intervention/   
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Table 2 Proposed primary and secondary outcome measures for a definitive trial used within pilot by assessment and participant  
type a 
 
Outcome Domain 
 
Participants 
 
Measure and derivation of outcome 
Baseline 
(T0) 
3- 
month 
(T1) 
6- 
month 
(T2) 
12 
month 
(T3) 
  Primary ED visits PWE Routine data, Hospital Episode Statistics Accident & Emergency system 
NHS numbers of patient participants securely transferred to NHS Digital who hold 
the Hospital Episode Statistics system. NHS Digital then provided the number of ED 
visits these patients were recorded as having made in the 12 months prior to and in 
the 12 months following their randomisation. b 
 
✓ - - ✓ 
  Secondary ED visits PWE Self-report, “How many times have you used Casualty / Accident & Emergency (A&E) 
over the past 12 months for epilepsy?” 
(For T2 the time frame was 6 months)  
Provided with seizure diary at T0 to assist. 
 
✓ - ✓ ✓ 
Seizure control PWE Baseline: Thapar’s65  Seizure Frequency Scale for the prior 12 months. 
T2 and T3: Asked for number of epileptic seizures (of any type) since last assessment 
and dates of the first and most recent. Provided with seizure diary at T0 to assist. 
 
✓ - ✓ ✓ 
Quality of life  PWE Quality of Life in Epilepsy Scale-31-P (31 items) 66  
 
✓ - ✓ ✓ 
Distress PWE; SOs Hospital Anxiety and Depression Scale (14 items) 67 c ✓ - - ✓ 
Felt Stigma PWE; SOs Stigma of Epilepsy Scale (9 items) 68  d ✓ - - ✓ 
Burden SOs Zarit Caregiver Burden Inventory (22 items) 50 e ✓ - ✓ ✓ 
Adverse events PWE Monitored by PWE completing a checklist. f 
 
- ✓ ✓ ✓ 
Fear of seizures 
 
PWE; SOs Epilepsy Knowledge and Management Questionnaire – Fears subscale (5 items) 69 ✓ - - ✓ 
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Knowledge of what to do 
when faced with a 
seizure 
 
PWE; SOs Thinking About Epilepsy Questionnaire (13 items)70  
 
✓ - - ✓ 
Confidence managing 
seizures/ epilepsy 
PWE; SOs PWE: Epilepsy Mastery Scale (6 items) 71 
SOs: Parents Response to Child Illness Scale- Condition Management subscale (6 
items) 72 
✓ - ✓ ✓ 
Health economics PWE Client Service Receipt Inventory 73 and EQ-5D (13 items) 74  ✓ - - ✓ 
- Feedback on trial 
participation 
PWE; SOs 
 
Adapted from Magpie Trial (3 items) 75  
(1) “If time suddenly went backward, and you had to do it all over again, would you 
agree to participate in the Seizure First Aid Training trial?”;       
(2) “Please tell us if there was anything about the Seizure First Aid Training Trial that 
you think could have been done better”;  
(3) “Please tell us if there was anything about the Seizure First Aid Training Trial, or 
your experience of joining the trial, that you think was particularly good” 
- - - ✓ 
Notes:  
ED= Emergency Department; PWE= Person with epilepsy; SOs= Significant others.  
a Unless a patient formally withdrew consent to participate in the trial, routine data on their ED use was requested and up to 3 attempts were made to contact patients 
or SO participant each time one of their follow-up assessments was due.  
b To minimise cost, a single application for routine data was submitted, rather than one relating to the baseline period and one for follow-up.  
c  Total anxiety and total depression scores were categorised according to the following: 0 to 7, ‘Normal range’; 8 to 10, ‘Suggestive of anxiety / depression’; 11 to 21, 
‘Probable anxiety / depression.’ 
d Total stigma scores were categorised as follows: 0, ‘No stigma’; 1 to 6, ‘Mildly to moderately stigmatized’; 7 to 9, ‘Highly stigmatized;  
e Total Zarit Burden scores were categorised as follows: 0 to 20, ‘Little or no burden’, 21 to 40, ‘Mild to moderate burden’, 41 to 60, ‘Moderate to severe burden’; 61 
to 88, ‘Severe burden.’ 
f Definitions of serious adverse event and how relatedness was assessed is presented in Supplementary File 9.  
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Table 3  Participant inclusion and exclusion criteria 
Notes:  
Patient participants were permitted to take part without a carer. Carers could not, however, take part 
without a patient partner having at least consented to take part into the study. 
Participants Inclusion criteria Exclusion criteria 
    Patients • Established diagnosis of epilepsy 
(≥1 year); 
• All epilepsy syndromes and all 
types of focal and generalised 
seizures; 
• Currently being prescribed 
antiepileptic medication; 
• Age ≥16 years (no upper age 
limit); 
• Visited an ED for epilepsy on ≥2 
occasions within the previous 12 
months (as reported by patient); 
• Live within 25 miles of any of the 
ED recruitment sites; 
• Able to provide informed 
consent, participate in 
intervention and independently 
complete questionnaires in 
English. 
 
• Actual or suspected psychogenic 
non-epileptic seizures alone or in 
combination with epilepsy; 
• Acute symptomatic seizures 
related to acute neurological 
illness or substance misuse; 
• Severe current psychiatric 
disorders (e.g. acute psychosis) 
or life-threatening medical 
illness; 
• Enrolled in other  epilepsy related 
non-pharmacological 
treatment studies. 
   Carers • A significant other to the patient 
(e.g., family member, friend) who 
the patient identifies as providing 
informal support; 
• Age ≥16 years (no upper age 
limit); 
• Lives in the North West  area of 
England 
• Severe current psychiatric 
disorders or life threatening 
medical illness; 
• Enrolled in other epilepsy related 
non-pharmacological 
treatment studies. 
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Table 4 Characteristics of eligible patients who did and did not agree to participate 
Variable Agreed to 
participate 
Did not agree to 
participate 
SAFE + TAU 
(n=26) 
TAU 
(n=25) 
Combined 
(n=51) 
 
(n=379)b 
Sex: n (%)     
Male 10 (38.5%) 12 (48.0%) 22 (43.1%) 192 (50.7%) 
Female 16 (61.5%) 13 (52.0%) 29 (56.9%) 187 (49.3%) 
Age at presentation to emergency department (years)     
Mean 39.2 40.7 39.9 40.6 
Standard deviation 13.96 17.52 15.66 16.83 
Median (min., max.) 37.1 (18.9, 69.9) 41.4 (16.5, 71.3) 38.8 (16.4, 71.3) 37.5 (16.2, 84.4) 
Index of Multiple Deprivation (IMD) a     
IMD Decile: 1 n (%) 11 (42.3%) 14 (56.0%) 25 (49.0%) 188 (49.6%) 
IMD Rank Median (min., max.) 574.0 (44, 3202) 1231.5 (48, 2166) 673.0 (44, 3202) 924.5 (28, 3107) 
IMD Decile: 2 to 3 n (%) 7 (26.9%) 6 (24.0) 13 (25.4%) 82 (21.6%) 
IMD Rank Median (min., max.) 6785 (4649, 8281) 6665 (3989, 7816) 6785 (3989, 8281) 5309 (3291,9835) 
IMD Decile: 4 to 6 n (%) 2 (7.7%) 4 (16.0%) 6 (11.8%) 59 (15.6%) 
IMD Rank Median (min., max.) 12836 (9881, 15791) 11924 (11480, 16004) 11924 (9881, 16004) 14459 (10277, 19659) 
IMD Decile: 7 to 10 n (%) 5 (19.2%) 1 (4.0%) 6 (11.8%) 50 (13.2%) 
IMD Rank Median (min., max.) 27642 (24971, 31002) 32724 (32724, 32724) 28876 (24971, 32724) 22673 (19826, 32396) 
 Missing 1 (3.8%) 0 (0.0%) 1 (2.0%) 0 (0.0%) 
Ethnicity: n (%)      
White 25 (96.2%) 23 (92.0%) 48 (94.1%) - 
Asian / Asian British 0 (0.0%) 0 (0.0%) 0 (0.0%) - 
Black / African / Caribbean / Black British 1 (3.8%) 1 (4.0%) 2 (3.9%) - 
Mixed / multiple ethnic groups 0 (0.0%) 0 (0.0%) 0 (0.0%) - 
Other ethnic group 0 (0.0%) 1 (4.0%) 1 (2.0%) - 
Other significant medical history: n (%)     
No, none 13 (50.0%) 10 (40.0%) 23 (45.1%) - 
Yes, another medical condition/s 10 (38.5%) 13 (52.0%) 23 (45.1%) - 
25 
 
 
Notes:  
a The Index of Multiple Deprivation (IMD) ranks every small area in England from 1 (most deprived area) to 32,844 (least deprived area).IMD rank and decile missing 
for one recruited participant as they resided in Wales.; b Includes seven patients who could not be contacted due to an incorrect postal address and two patients who 
were not sent an invite letter in error.min.= minimum, max.= maximum. 
 
Yes, a psychiatric condition 1 (3.8%) 0 (0.0%)   1 (2.0%) - 
Yes, both medical and psychiatric conditions 2 (7.7%) 2 (8.0%) 4 (7.8%) - 
Education: n (%)     
O' levels/ GCSEs/ Level 1 or 2 NVQ 13 (50.0%) 14 (56.0%) 27 (53.0%) - 
A' Levels/ Level 3 NVQ 5 (19.2%) 3 (12.0%) 8 (15.7%) - 
University degree/ Graduate Certificate or Diploma 5 (19.2%) 5 (20.0%) 10 (19.6%) - 
Postgraduate university degree (e.g., PGCE, MSc, MA, PhD) 2 (7.7%) 0 (0.0%) 2 (3.9%) - 
Missing 1 (3.9%) 3 (12.0%) 4 (7.8%) - 
Time since epilepsy diagnosis (years)     
Mean 19.9 22.6 21.2 - 
Standard deviation 14.85 18.38 16.57 - 
Median (mix., max.) 16.8 (1.8, 53.9) 19.3 (1.7, 64.9) 17.3 (1.7, 64.9) - 
Time since last epileptic seizure (days)     
Mean 53.6 40.1 47.0 - 
Standard deviation 101.10 61.21 83.34 - 
Median (min., max.) 14.0 (1, 340) 10.5 (0, 235) 14.0 (0, 340) - 
Missing 3 (11.5%) 3 (12.0%) 6 (11.8%) - 
Number of epileptic seizures in the last 12 months     
0-3 4 (15.3%) 3 (12.0%) 7 (13.8%) - 
4-6 1 (3.8%) 5 (20.0%) 6 (11.7%) - 
7-9 3 (11.5%) 3 (12.0%) 6 (11.7%) - 
10 or more 18 (69.2%) 14 (56.0%) 32 (62.8%) - 
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Table 5 Number of ED visits patient participants made according to routine data  
Number of ED visits 
 
SAFE+TAU 
(n=26) 
TAU 
(n=25) 
Total 
(n=51) 
In the 12 months  
to baseline 
Mean 2.1 3 2.5 
Standard deviation 2.22 2.76 2.51 
Median (min., max.) 1 (0, 10) 2 (1, 12) 2 (0, 12) 
Missing 1 (3.8%) 2 (8.0%) 3 (5.9%) 
In the 12 months 
following 
randomisation 
 
Mean 1.8 3.4 2.6 
Standard deviation 3.14 4.78 4.05 
Median (min., max.) 1 (0, 12) 2 (0, 20) 1 (0, 20) 
Missing 1 (3.8%) 2 (8.0%) 3 (5.9%) 
 
Change from baseline 
over 12 months 
following 
randomisation  
Mean -0.3 0.4 0.1 
Standard deviation 1.99 3.81 2.99 
Median (min., max.) 0 (-4, 5) 0 (-5, 16) 0 (-5, 16) 
Missing 
1 (3.8%) 2 (8.0%) 3 (5.9%) 
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Table 6 Between intervention group differences in number of ED visits 
Model and parameter Parameter Confidence Interval (CI) P-value 
95% 90% 80% 
12 months following randomisation according to routine dataa 
Negative binomial: SAFE + TAU (Rate Ratio)  0.54 0.24 to 1.18 0.28 to 1.04 0.32 to 0.90 0.12 
Negative binomial: Dispersion parameter 1.53 0.67 to 2.39 0.80 to 2.25 0.96 to 2.09 NA 
Vuong’s Testb -0.17 NA NA NA 0.87 
12 months following randomisation according to routine data with adjustment for baseline ED visits 
Negative binomial: SAFE + TAU (Rate Ratio) 0.62 0.33 to 1.17 0.36 to 1.06 0.41 to 0.94  0.14 
Negative binomial: Baseline ED visits (Rate Ratio) 1.33 1.18 to 1.52 1.20 to 1.49 1.23 to 1.45 <0.001 
Negative binomial: Dispersion parameter 0.69 0.17 to 1.21 0.26 to 1.13 0.35 to 1.03 NA 
Vuong’s Testb -0.13 NA NA NA 0.90 
Notes: 
ED=Emergency Department; SAFE=Seizure First Aid Training; TAU=Treatment-As-Usual,  
a Analysis based on 48 patient participants  
b Vuong’s test p-value interpretation, a significantly negative parameter value favours the Negative 
Binomial model and significantly positive favours the Zero-inflated Negative Binomial model. A non-
significant value indicates no significant difference between the models therefore the simpler Negative 
Binomial model is preferred.76  
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Table 7 Required sample size for a definitive trial to detect estimated effect of 
SAFE+TAU on ED use 
 
Dispersion parameter (k) 
~47% reduction (from 3.4 to 1.8 visits) in 12 months 
compared to TAU 
n per group 
(α= 0.05; 80% power, β=0.2) 
n per group 
(α= 0.05; 90% power, β=0.1) 
0.17 123 164 
0.5 191 255 
0.69 230 308 
1 293 393 
1.21 337 451 
 Notes:  
Dispersion parameter taken from the adjusted NBR model in the pilot RCT (i.e., k=0.69; 95% CI: 0.17 
to 1.21); see Table 6   
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Figure Legend 
 
Figure 1 CONSORT diagram of flow through the pilot trial 
Figure 2 a) Bland Altman plot of agreement between self-reported ED use and routine 
data on ED use in 12 months prior to randomisation; b) Bland Altman plot of 
agreement between self-reported ED visits and routine data on ED use over 
12 months following randomisation. 
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